GSK launches hostile $2.6 bn bid for Human Genome Sciences

May 9, 2012 in Medications

British drugmaker GlaxoSmithKline on Wednesday said it had gone hostile over its $2.6 billion (2.0 billion-euro) takeover bid for US research partner Human Genome Sciences Inc.

GlaxoSmithKline, which in April had an informal offer rejected by the US company's board, said it had decided to put its bid directly to the shareholders of HGS. The offer remains $13 per share in cash.

" today announced that it will ... commence a tender offer this week to acquire all of the outstanding shares of HGS for $13.0 per share in cash," the British firm said.

"GSK's offer represents a premium of 81 percent to HGS's closing share price of $7.17 on 18th April, the last trading day before HGS publicly disclosed GSK's private offer."

(c) 2012 AFP

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

Breakup of physician, drug company relationship could improve health care, cut cost

A new report suggests that improved health care and significant reductions in drug costs might be attained by breaking up the age-old relationship between physicians and drug company representatives who promote the newest, ...

Medications created 18 hours ago | popularity 5 / 5 (1) | comments 0

FDA has safety concerns on Merck insomnia drug

Federal health regulators say an experimental insomnia drug from Merck can help patients fall asleep, but it also carries worrisome side effects, including daytime drowsiness and suicidal thinking.

Medications created 20 hours ago | popularity not rated yet | comments 0

US adviser on board of firm that sold anthrax drug

(AP)—Former Navy Secretary Richard J. Danzig, who has served as a bio-warfare adviser to the president, the Pentagon, and the Department of Homeland Security, urged the government to stockpile an anti-anthrax drug while ...

Medications created May 20, 2013 | popularity 5 / 5 (1) | comments 0

Acne pill benefits outweigh blood clot risk: EU agency

Europe's medicines watchdog said Friday the benefits of acne drug Diane-35, also widely used as a contraceptive, outweigh the risk of developing blood clots in the veins—when correctly prescribed.

Medications created May 17, 2013 | popularity not rated yet | comments 0

First influenza vaccine brought to clinical testing

Singapore's Agency for Science, Technology and Research (A*STAR) and Switzerland's Cytos Biotechnology AG today announced that the first healthy volunteer has been dosed in a Phase 1 clinical trial with their ...

Medications created May 17, 2013 | popularity 5 / 5 (1) | comments 1


Anti-CD47 antibody may offer new route to successful cancer vaccination

(Medical Xpress)—Scientists at the School of Medicine have shown that their previously identified therapeutic approach to fight cancer via immune cells called macrophages also prompts the disease-fighting killer T cells ...

Evaluating a new way to open clogged arteries

Over the past few decades, scientists have developed many devices that can reopen clogged arteries, including angioplasty balloons and metallic stents. While generally effective, each of these treatments ...

Biomarker trio predicts near-term heart risk

(Medical Xpress)—Cardiologists have identified a trio of biomarkers that may predict which patients with heart disease have a high risk of heart attack or death in the next two years.

Primary care docs should play role in kids' dental health, experts say

(HealthDay)—When it comes to the care of your children's teeth, dentists aren't the only experts who can help.

New theory offers clues to vital 'repair and maintenance' role of sleep

(Medical Xpress)—We spend about a third of our life asleep, but why we need to do so remains a mystery. In a recent publication, researchers at University of Surrey and University College London suggest a new hypothesis, ...

Salt consumption in India: The need for data to initiate population-based prevention efforts

(Medical Xpress)—International researchers are studying the salt intake of Indian adults to provide vital new data to aid the development of a national salt reduction strategy.